drugset / Trial / NCT05293548
A Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) and Inactivated COVID-19 Vaccine (Vero Cell)
Phase 2
Unknown
516 enrolled
National Vaccine and Serum Institute, China
Beijing Institute of Biological Products Co Ltd. · collabChina National Biotec Group Company Limited · collabLanzhou Institute of Biological Products Co., Ltd · collab
RandomizedParallel-groupDouble-blindPrevention
Summary
A total of 516 healthy subjects aged 18 years and above who have been vaccinated with 2 doses/3 doses of inactivated COVID-19 vaccine, will be enrolled, and randomly assigned to experimental group and control group in a 1:1 ratio, with 258 subjects in each sequential group.
Timeline
- Start
- 2022-05-25
- Primary completion
- 2023-05
- Completion
- 2023-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Inactivated COVID-19 vaccine (Vero cells) | Vaccine | — | Intramuscular |
| Subject | NVSI-06-09 | Vaccine | — | Intramuscular |